



Draft Genome Sequence of the Biofilm-Forming Stenotrophomonas maltophilia Strain 53

Sirwan Akbar, Simon P. Rout, Paul N. Humphreys

Department of Biological Sciences, School of Applied Sciences, University of Huddersfield, Huddersfield, United Kingdom

A clinical strain of *Stenotrophomonas maltophilia* (designated strain 53) was obtained, and a whole-genome sequence was generated. The subsequent draft whole-genome sequence demonstrated the presence of a number of genes encoding for proteins involved in resistance to a number of antimicrobial therapies.

Received 5 March 2015 Accepted 9 March 2015 Published 16 April 2015

Citation Akbar S, Rout SP, Humphreys PN. 2015. Draft genome sequence of the biofilm-forming Stenotrophomonas maltophilia strain 53. Genome Announc 3(2):e00312-15. doi:10.1128/genomeA.00312-15.

Copyright © 2015 Akbar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported license.

Address correspondence to Paul N. Humphreys, p.n.humphreys@hud.ac.uk.

tenotrophomonas maltophilia is an aerobic, Gram-negative, and nonfermentative microorganism, originally described as Bacterium booker in 1943 before being placed in the novel genus Stenotrophomonas in 1993 (1). Strains of Stenotrophomonas maltophilia have been found almost ubiquitously within natural environments, including freshwater sources, and within both the soil and plant microbiomes (2-4). This species has received attention with regard to its bioremediation properties, where the degradation of a number of contaminants has been described (5, 6). Within a clinical setting, members of this species also represent a risk of nosocomial infection, where it is an opportunistic pathogen to immunosuppressed or debilitated individuals (7, 8). Mechanisms such as decreased permeability, β -lactamases, aminoglycoside-modifying enzymes, and the presence of efflux pumps within the outer membrane aid this pathogenicity (9). This resistance appears to be mediated not only by intrinsic resistance mechanisms but also through its ability to acquire resistance via uptake and integration of genetic information into the host chromosome (10).

A hospital isolate of Stenotrophomonas maltophilia was obtained and subcultured into tryptone soya broth. Following incubation for 24 h at 37°C, total genomic DNA was isolated using a commercial kit (Ultraclean microbial isolation kit; Mo-Bio, USA). A draft whole-genome sequence was obtained using a wholegenome shotgun sequence strategy. Paired-end 125-cycle sequence reads were generated using Illumina HiSeq 2500 technology (BaseClear, Netherlands). FASTQ sequence files were generated using the Illumina CASAVA pipeline version 1.8.3, and the CLC Genomics Workbench version 7.0 was used for assembly. The contigs were linked and placed into scaffolds or supercontigs. The orientation, order, and distance between the contigs were estimated using the insert size between the paired-end and/or mate-pair reads using the SSPACE Premium scaffolder version 2.3 (11). Whole-genome sequencing generated 128 contigs with a draft genome 4,637,878 bp in length and a G+C content of 66.3%. The draft genome contained a total of 4,082 coding sequences (CDS), where 77 pseudogenes, 3 genes coding for rRNA (5S, 16S, 23S), 64 genes coding for tRNAs, and 1 noncoding RNA

were present. RAST (12) annotation showed that 31 genes were present encoding multidrug-resistance efflux pumps, 21 were involved in cobalt-zinc-cadmium resistance and 10 genes were involved in the production of β -lactamases. Also present were genes involved in resistance to arsenic and fluoroquinolones, as well as tripartite efflux pumps and a single gene encoding an aminogly-coside adenylyltransferase. In addition, genes were present that were responsible for encoding proteins involved in the synthesis of biofilms, which are likely to enhance its pathogenicity (13). Overall, the strain demonstrates the potential for resistance to a wide range of antimicrobial strategies within the clinical setting.

Nucleotide sequence accession number. This whole-genome shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession number JRJA00000000.

ACKNOWLEDGMENTS

We thank Jane Turton, Laboratory of Health Care Associated Infection, Health Protection Agency, London, United Kingdom, for providing the isolate.

We received no external funding in support of this work.

REFERENCES

- 1. Palleroni NJ, Bradbury JF. 1993. *Stenotrophomonas*, a new bacterial genus for *Xanthomonas maltophilia* (Hugh 1980) Swings et al. 1983. Int J Syst Bacteriol 43:606–609. http://dx.doi.org/10.1099/00207713-43-3-606.
- Hoefel D, Monis PT, Grooby WL, Andrews S, Saint CP. 2005. Profiling bacterial survival through a water treatment process and subsequent distribution system. J Appl Microbiol 99:175–186. http://dx.doi.org/ 10.1111/j.1365-2672.2005.02573.x.
- Vazquez S, Ruberto L, Mac Cormack W. 2005. Properties of extracellular proteases from three psychrotolerant *Stenotrophomonas maltophilia* isolated from Antarctic soil. Polar Biol 28:319–325. http://dx.doi.org/ 10.1007/s00300-004-0673-6.
- Dungan RS, Yates SR, Frankenberger WT. 2003. Transformations of selenate and selenite by *Stenotrophomonas maltophilia* isolated from a seleniferous agricultural drainage pond sediment. Environ Microbiol 5:287–295. http://dx.doi.org/10.1046/j.1462-2920.2003.00410.x.
- Binks PR, Nicklin S, Bruce NC. 1995. Degradation of hexahydro-1, 3,5-trinitro-1,3,5-triazine (RDX) by Stenotrophomonas maltophilia PB1. Appl Environ Microbiol 61:1318–1322.
- Boonchan S, Britz ML, Stanley GA. 1998. Surfactant-enhanced biodegradation of high molecular weight polycyclic aromatic hydrocarbons by

- *Stenotrophomonas maltophilia*. Biotechnol Bioeng **59:**482–494. http://dx.doi.org/10.1002/(SICI)1097-0290(19980820)59:4<482::AID-BIT11 @ 0 0 3 e 3 . 3 . C O ; 2 T.
- Sanchez MB, Hernandez A, Martinez JL. 2009. Stenotrophomonas maltophilia drug resistance. Future Microbiol 4:655–660. http://dx.doi.org/ 10.2217/fmb.09.45.
- Brooke JS. 2012. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 25:2–41. http://dx.doi.org/ 10.1128/CMR.00019-11.
- 9. Samonis G, Karageorgopoulos DE, Maraki S, Levis P, Dimopoulou D, Spernovasilis NA, Kofteridis DP, Falagas ME. 2012. *Stenotrophomonas maltophilia* infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome. PLoS One 7:e37375. http://dx.doi.org/10.1371/journal.pone.0037375.
- 10. Hu L.-F, Chang X, Ye Y, Wang Z.-X, Shao Y.-B, Shi W, Li X, Li J.-B. 2011. Stenotrophomonas maltophilia resistance to trimethoprim/

- sulfamethoxazole mediated by acquisition of *sul* and *dfrA* genes in a plasmid-mediated class 1 integron. Int J Antimicrob Agents 37:230–234. http://dx.doi.org/10.1016/j.ijantimicag.2010.10.025.
- 11. Boetzer M, Henkel CV, Jansen HJ, Butler D, Pirovano W. 2011. Scaffolding pre-assembled contigs using SSPACE. Bioinformatics 27: 578–579. http://dx.doi.org/10.1093/bioinformatics/btq683.
- Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD. 2008. The RAST server: Rapid Annotations using Subsystems Technology. BMC Genomics 9:75. http://dx.doi.org/10.1186/1471-2164-9-75.
- 13. Liaw S.-J, Lee Y.-L, Hsueh P.-R. 2010. Multidrug resistance in clinical isolates of *Stenotrophomonas maltophilia*: roles of integrons, efflux pumps, phosphoglucomutase (SpgM), and melanin and biofilm formation. Int J Antimicrob Agents 35:126–130. http://dx.doi.org/10.1016/j.ijantimicag.2009.09.015.